Alzheimer’s disease is a common and devastating neurodegenerative condition that represents an enormous burden for patients, families, and health care systems.  Effective disease-modifying therapies for AD have been elusive, and AD remains one of the major health challenges facing our society.  My laboratory uses a broad array of complimentary tools – ranging from biochemical models to neuroimaging to novel wearable devices – to better understand Alzheimer’s disease biology and identify targets for novel therapies.  I am a practicing neurologist who cares for patients with neurodegenerative diseases, with a particular focus on early-onset and genetically-driven Alzheimer’s disease. My laboratory has active projects in neuroimaging with MRI and PET, blood-based Alzheimer’s disease biomarkers, cell-based models of Alzheimer’s biology, genetics, and sleep. I lead research on vascular, sleep-related, and inflammatory influences on late life cognitive decline as part of the Harvard Aging Brain Study (HABS) and the SONNET study.  Working together with a diverse and talented group of investigators, fellows, and students, I direct the Biomarkers of Neurodegeneration, Inflammation, and Cognitive decline (BioNIC) laboratory at BWH and MGH.  BioNIC brings together neuroimaging, clinical, and biochemical experts on Alzheimer’s disease with the goal of developing new biomarkers that elucidate disease mechanisms, identify key targets for future drugs, and accelerate the testing of novel therapies.